Results 81 to 90 of about 539 (92)

Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration (Ophthalmology. 2021;128:576–586)

Ophthalmology, 2021
Maximilian Pfau
exaly  

Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial (Ophthalmology. 2021;128:576–586)

Ophthalmology, 2021
Tiarnán Keenan
exaly  

Avacincaptad Pegol Sodium

American Journal of Health-System Pharmacy, 2023
exaly  

Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy

Journal of Vitreoretinal Diseases
Charles Wykoff, Dilsher Dhoot, Paul Hahn   +2 more
exaly  

Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy

Ophthalmology Retina
Peter Kaiser, Aleksandra Rachitskaya, Julie Clark   +2 more
exaly  

Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study

American Journal of Ophthalmology
Peter Kertes, Marko Popovic, Rajeev Muni   +2 more
exaly  

Update on Avacincaptad Pegol for Geographic Atrophy

2022
exaly  

Avacincaptad pegol in geographic atrophy secondary to age-related macular degeneration: a profile of its use

Drugs and Therapy Perspectives
Amy Zhuang-Yan
exaly  

A Cost Effectiveness Analysis of Avacincaptad Pegol for the Treatment of Geographic Atrophy with Comparison to Pegcetacoplan

Ophthalmology Retina
Hasenin Al-Khersan, William Smiddy, Nimesh Patel   +2 more
exaly  

Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Ophthalmology
Roberto Gallego-Pinazo, András Seres, Sunil Patel   +2 more
exaly